Table 2.
Best response, objective response rate, and disease control rate during lenvatinib treatments
| Any patients (n = 152) |
Child-Pugh class |
Prior systemic therapy |
High burden of intrahepatic lesion |
||||
|---|---|---|---|---|---|---|---|
| A (n = 132) | B (n = 20) | absent (1st line) (n = 95) | present (2nd line or later) (n = 57) | absent (n = 125) | present (n = 27) | ||
| RECIST | |||||||
| Complete response | 2 (1) | 2 (2) | 0 | 2 (2) | 0 | 1 (1) | 1 (4) |
| Partial response | 22 (15) | 21 (16) | 1 (5) | 14 (15) | 8 (14) | 17 (14) | 5 (19) |
| Stable disease | 78 (51) | 67 (51) | 11 (55) | 47 (50) | 31 (54) | 69 (56) | 9 (33) |
| Progressive disease | 29 (19) | 24 (18) | 5 (25) | 17 (18) | 12 (21) | 21 (17) | 8 (30) |
| Objective response rate | 24 (16) | 23 (18) | 1 (5) | 16 (17) | 8 (14) | 18 (15) | 6 (23) |
| Disease control rate | 102 (67) | 90 (68) | 12 (60) | 63 (66) | 39 (68) | 87 (70) | 15 (56) |
| mRECIST | |||||||
| Complete response | 3 (1) | 3 (2) | 0 | 2 (2) | 1 (2) | 3 (2) | 0 |
| Partial response | 59 (39) | 49 (37) | 10 (50) | 40 (42) | 19 (33) | 48 (38) | 11 (41) |
| Stable disease | 42 (27) | 39 (30) | 3 (15) | 23 (24) | 19 (32) | 34 (27) | 8 (30) |
| Progressive disease | 27 (18) | 24 (18) | 3 (15) | 14 (15) | 13 (23) | 22 (18) | 5 (19) |
| Objective response rate | 62 (41) | 52 (39) | 10 (50) | 42 (44) | 20 (35) | 51 (41) | 11 (41) |
| Disease control rate | 104 (68) | 91 (60) | 13 (65) | 65 (68) | 39 (68) | 85 (68) | 24 (70) |
RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST.